glp 1 receptor agonists in idiopathic intracranial hypertension GLP-1 may improve outcomes Efficacy of glucagon-like peptide-1 receptor

113 Patients with active UC and CD had higher amounts of bioactive GLP-2 than healthy controls, according to a study by Xiao et al

Much of the current evidence on humans comes from large observational studies using health record data rather than randomized clinical trials

doi: 10.1016/j.ejphar.2010.10.008 33 BertilssonGPatroneCZachrissonOAnderssonADannaeusKHeidrichJet al

As the chart below shows, the arms race is accelerating

Arguments for Game Changer Status Several compelling arguments support the characterization of GLP-1 agonists as transformative therapies: Unprecedented Efficacy : Tirzepatide marks a new era in overweight/obesity treatment, enabling many to achieve 20% weight loss [76] [77]

potential FDA submission 2028 (estimated): Possible FDA approval and commercial availability In the meantime, FDA-approved weight loss medications are available now